A pooled analysis of individual patient data from the major bivalirudin versus unfractionated heparin trials concludes that preprocedural bivalirudin could be considered the agent of choice in the ...

In 1988, Wheeler et al. [8] reported that physicians treating patients for pulmonary embolism and deep-vein thrombosis frequently underdosed their patients and were slow to change their heparin ...

This was a single-center, observational cohort study conducted at an 852-bed academic medical center. The study involved a review of electronic and paper medical records of patients who received ...

LONDON, England—In ACS patients receiving PCI, bivalirudin reduces major bleeding and mortality but not net adverse clinical events (NACE) vs heparin, according to results presented September 1, 2015, ...

We conducted a study of patients with acute pulmonary embolism and pulmonary hypertension or right ventricular dysfunction but without arterial hypotension or shock. The patients were randomly ...

18F-Fluorodeoxyglucose Positron Emission Tomography Contributes to the Diagnosis and Management of Infections in Patients With Multiple Myeloma: A Study of 165 Infectious Episodes Two hundred and ...

Bivalirudin is a safer and more effective anticoagulant than heparin for treating patients with the most serious type of heart attacks who undergo urgent percutaneous coronary intervention (PCI), and ...

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today it has introduced in the United States two new presentations of Heparin Sodium in convenient, ready-to-administer Freeflex ® IV bags.

A new study could change the treatment course for hundreds of thousands of patients, saving lives and preventing complications. Bivalirudin is a safer and more effective anticoagulant than heparin for ...